ATOSSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ATOSSA THERAPEUTICS, INC. (ATOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2022-02-28
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-12-31 was $348.00.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-12-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2015-06-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $2.75M, a 826.49% increase from fiscal 2020.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $297.25K.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $69.39K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2021-12-31 | $348.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.75M 10-K · filed 2022-02-28 | ||
| 2021-09-30 | $2.75M 10-Q · filed 2021-11-15 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $297.25K 10-K · filed 2021-03-31 | ||
| 2020-09-30 | $297.25K 10-Q · filed 2020-11-13 | |||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $0.00 derived: sum of 2 quarters · filed 2015-11-12 | $0.00 10-Q · filed 2015-11-12 | $0.00 derived: sum of 4 quarters · filed 2015-11-12 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2015-08-06 | $54.99K derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-13 | $0.00 derived: sum of 2 quarters · filed 2015-05-13 | $54.99K derived: sum of 3 quarters · filed 2015-05-13 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $54.99K derived: sum of 2 quarters · filed 2015-03-30 | $69.39K 10-K · filed 2015-03-30 | |
| 2014-09-30 | $54.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $69.39K 10-Q · filed 2014-11-12 | ||
| 2014-06-30 | $14.40K 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |